| Literature DB >> 29516902 |
Neha Sharma1, Rajeshwari G Annigeri1.
Abstract
This review summarizes and interprets the rate of improvement in cancer treatments which have remained frustratingly slow despite considerable investment in oncological research. Hence, this review emphasizes on minimizing exposure of patients to ineffective investigational therapies by decreasing the number of poorly designed clinical trials through stronger collaboration between industry and academia which can be done by multidisciplinary teams who are essential to facilitate future cancer outcome studies focused on improving clinical care of cancer patients and implementing effective interventions to ultimately improve the quality and duration of survival. Hence, it is recommended to explore all these factors which contribute toward translational lag between implementation of discoveries from basic research into clinical use.Entities:
Keywords: Biomarkers; personalized medicine; translational research; tumorigenesis
Mesh:
Substances:
Year: 2018 PMID: 29516902 DOI: 10.4103/0973-1482.183556
Source DB: PubMed Journal: J Cancer Res Ther ISSN: 1998-4138 Impact factor: 1.805